

acting as investment or financial advisory to any person pursuant to section 225.28(b)(6) of Regulation Y; acting as a futures commission merchant pursuant to section 225.28(b)(7)(iv) of Regulation Y.

**B. Federal Reserve Bank of Kansas City** (James Hunter, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *First Centralia Bancshares, Inc.*, Centralia, Kansas; to acquire up to 41.34 percent of FBC Financial Corporation, and thereby indirectly acquire 1st Bank Oklahoma, both of Claremore, Oklahoma, and thereby engage in operating a savings association, pursuant to section 225.28(b)(4)(ii) of Regulation Y. Comments regarding this application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 24, 2003.

2. *Morrill Bancshares, Inc.*, Merriam, Kansas; to acquire up to 41.34 percent of FBC Financial Corporation, and thereby indirectly acquire 1st Bank Oklahoma, both of Claremore, Oklahoma, and thereby engage in operating a savings association, pursuant to section 225.28(b)(4)(ii) of Regulation Y. Comments regarding this application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 24, 2003.

3. *Davis Bancorporation, Inc.*, Davis, Oklahoma; to acquire up to 13.78 percent of FBC Financial Corporation, and thereby indirectly acquire 1st Bank Oklahoma, both of Claremore, Oklahoma, and thereby engage in operating a savings association, pursuant to section 225.28(b)(4)(ii) of Regulation Y. Comments regarding this application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 24, 2003.

Board of Governors of the Federal Reserve System, September 24, 2003.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 03-24631 Filed 9-29-03; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Sunshine Act Meeting Notice

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

**TIME AND DATE:** 11:30 a.m., Monday, October 6, 2003.

**PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

**STATUS:** Closed.

#### MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

#### FOR FURTHER INFORMATION CONTACT:

Michelle A. Smith, Director, Office of Board Members; 202-452-2953.

**SUPPLEMENTARY INFORMATION:** You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: September 26, 2003.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 03-24952 Filed 9-26-03; 4:08 pm]

**BILLING CODE 6210-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Vaccine Advisory Committee

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (DHHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold a meeting. The meeting is open to the public.

**DATES:** The meeting will be held on October 7, 2003, from 9 a.m. to 5 p.m., and on October 8, 2003, from 8:30 a.m. to 3:15 p.m.

**ADDRESSES:** Department of Health and Human Services; Room 705A Humphrey Building; 200 Independence Avenue, SW., Washington, DC 20201.

**FOR FURTHER INFORMATION CONTACT:** Ms. Carolin Commodore, Staff Assistant, National Vaccine Program Office and Executive Secretary, National Vaccine Advisory Committee; U.S. Department of Health and Human Services, Room 725H Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; (202) 260-1253.

**SUPPLEMENTARY INFORMATION:** Pursuant to Section 2101 of the Public Service Act (42 U.S.C. 300aa-1), the Secretary of

Health and Human Services was mandated to establish the National Vaccine Program (NVP) to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The Secretary designated the Assistant Secretary for Health to serve as the Director, NVP. The National Vaccine Advisory Committee (NVAC) was established to provide advice and make recommendations to the Director, NVP, on matters related to the program's responsibilities. Topics to be discussed at the meeting include: The Institute of Medicine's (IOM) vaccine safety reviews and the recent IOM report on vaccine financing; a status report on the nation's smallpox vaccine program, and an overview of the SARS vaccine research and development at the National Institutes of Health (NIH). Updates will be given on activities at the NIH's Vaccine Research Center, pandemic influenza preparedness planning, and a status report on the West Nile virus vaccine. A tentative agenda will be made available for review on the NVPO Web site.

Public attendance at the meeting is limited to space available. Individuals must provide a photo ID for entry into the Humphrey Building. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to five minutes per speaker. Any members of the public who wish to have printed material distributed to NVAC members should submit materials to the Executive Secretary, NVAC, whose contact information is listed above prior to close of business October 3, 2003. Preregistration is required for both public attendance and comment. Any individual who wishes to attend the meeting and/or participate in the public comment session should call the telephone number listed in the contact information to register.

The National Vaccine Program Office will be organizationally relocated to the Office of Public Health and Science on October 1. Due to administrative matters impacting this organizational relocation, this notice is being published less than 15 days in advance of the meeting.

Dated: September 24, 2003.

**Bruce G. Gellin,**

*Director, National Vaccine Program Office  
and Executive Secretary, National Vaccine  
Advisory Committee.*

[FR Doc. 03-24797 Filed 9-29-03; 8:45 am]

**BILLING CODE 4150-28-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Toxic Substances and Disease Registry

#### Citizens Advisory Committee on Public Health Service (PHS) Activities and Research at Department of Energy (DOE) Sites: Oak Ridge Reservation Health Effects Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Agency for Toxic Substances and Disease Registry (ATSDR) and the Centers for Disease Control and Prevention (CDC) announce the following meeting.

*Name:* Citizens Advisory Committee on PHS Activities and Research at DOE Sites: Oak Ridge Reservation Health Effects Subcommittee (ORRHES).

*Time and Date:* 12 (noon)-8 p.m., October 21, 2003.

*Place:* DOE Information Center, 475 Oak Ridge Turnpike, Oak Ridge, Tennessee 37830. Telephone: (865) 241-4780.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Background:* A Memorandum of Understanding (MOU) was signed in October 1990 and renewed in September 2000 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or "Superfund"). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

In addition, under an MOU signed in December 1990 with DOE and replaced by an MOU signed in 2000, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production and use. HHS has delegated program responsibility to CDC.

*Purpose:* This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, pertaining to CDC's and ATSDR's public health activities and research at this DOE site. Activities shall focus on providing the public with a vehicle to express concerns and provide advice and recommendations to CDC and ATSDR. The purpose of this meeting is to receive updates from ATSDR and CDC, and to address other issues and topics, as necessary.

*Matters To Be Discussed:* The agenda includes a discussion of the final Public Health Assessment on Uranium Release from the Y-12 plant, plan for addressing the Public Health Assessment on Iodine, description of cancer incidence review document, updates from the Public Health Assessment, Public Health Needs Assessment, Agenda, and Outreach and Communications Workgroup.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Lorine Spencer, Designated Federal Official, or Marilyn Palmer, Committee Management Specialist, Division of Health Assessment and Consultation, ATSDR, 1600 Clifton Road, NE., M/S E-32, Atlanta, Georgia 30333, telephone 1-888-42-ATSDR (28737), fax 404/498-1744.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and ATSDR.

Dated: September 24, 2003.

**Alvin Hall,**

*Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.*

[FR Doc. 03-24677 Filed 9-29-03; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Breast and Cervical Cancer Early Detection and Control Advisory Committee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Breast and Cervical Cancer Early Detection and Control Advisory Committee (BCCEDCAC).

*Times and Dates:*

9 a.m.-5 p.m., November 5, 2003.

9 a.m.-3 p.m., November 6, 2003.

*Place:* The Ritz-Carlton Buckhead, 3434 Peachtree Road, NE., Atlanta, Georgia 30326, Telephone: 404-237-2700.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The committee is charged with advising the Secretary, Department of Health and Human Services, and the Director, CDC, regarding the early detection and control of breast and cervical cancer. The committee makes recommendations regarding national program goals and objectives; implementation strategies; and program priorities including surveillance, epidemiologic investigations, education and training, information dissemination, professional interactions and collaborations, and policy.

*Matters To Be Discussed:* The agenda will include a review and discussion of the National Breast and Cervical Cancer Early Detection Program components; professional education, screening, tracking, follow-up and case management, coalitions and partnerships, quality assurance and improvement, public education and outreach; update of the implementation of the treatment act; review of program announcement 2060, the National Cancer Prevention and Control Program; and discussion and review of related policies and emerging issues.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Debra Younginger, Executive Secretary, BCCEDCAC, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop K-57, Chamblee, Georgia 30316, Telephone: 770-488-1074.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 24, 2003.

**Alvin Hall,**

*Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.*

[FR Doc. 03-24676 Filed 9-29-03; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee for Injury Prevention and Control

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee and committee meetings.

*Name:* Science and Program Review Subcommittee (SPRS), meetings of the Advisory Committee for Injury Prevention and Control, and its subcommittees, the Science and Program Review Subcommittee